Systemic therapy of myeloma xenografts by an attenuated measles virus.

@article{Peng2001SystemicTO,
  title={Systemic therapy of myeloma xenografts by an attenuated measles virus.},
  author={Kah Whye Peng and G J Ahmann and Linh D. Pham and Philip R. Greipp and Roberto Cattaneo and Stephen J. Russell},
  journal={Blood},
  year={2001},
  volume={98 7},
  pages={
          2002-7
        }
}
Conditionally replicating viruses are promising agents for the treatment of malignancy. Here it is shown that the live attenuated Edmonston-B vaccine strain of measles virus (MV-Edm) replicates selectively in human myeloma cells and has potent antitumor activity. In vitro, replication of MV-Edm was restricted in phytohemagglutinin (PHA)-stimulated peripheral blood lymphocytes (PBLs) but proceeded efficiently in a panel of 6 myeloma cell lines-ARH-77, RPMI 8226, JJN-3, MM1, KAS-6/1, and KMS-11… 
View on PubMed
bloodjournal.org
196 Citations
Highly Influential Citations
2
Background Citations
63
Methods Citations
12
Results Citations
6

196 Citations

Citation Type

Citation Type

Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo.
TLDR
The data demonstrate the potential of MV as a therapeutic agent against CTCL and investigate in detail, the effect of recombinant MV (rMV) vaccine strain in CTC lysis cell cultures, and in vivo in established C TCL xenografts in nude mice.
Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.
TLDR
It is demonstrated for the first time that systemically administered cells can serve as MV carriers and prolonged survival of mice with pre-existing antimeasles antibodies are prolonged.
Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker.
TLDR
A new specificity domain against the plasma cell marker CD38 was constructed in the form of a single-chain antibody (scFv) and display of that scFv on the measles viral envelope glycoprotein successfully redirected virus entry through CD38 expressed on target cells devoid of the natural MV receptors.
Intraperitoneal therapy of ovarian cancer using an engineered measles virus.
Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies
Neutralizing antiviral antibodies (Abs) can hinder systemic virotherapy. Here, we used activated T cells as carriers to deliver oncolytic measles viruses (MV) to multiple myeloma xenografts in the…
An immunocompetent murine model for oncolysis with an armed and targeted measles virus.
TLDR
This immunocompetent murine model facilitates the testing of therapeutic regimens for clinical trials with the oncolytic measles virus, revealing synergistic effects between virus and prodrug.
An oncolytic measles virus engineered to enter cells through the CD20 antigen.
Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.
TLDR
Preclinical efficacy and safety data for engineered oncolytic MV-Edm derivatives that led to their clinical translation are discussed, and an overview of the early experience in three ongoing clinical trials of patients with ovarian cancer, glioblastoma multiforme and multiple myeloma is provided.
A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer
TLDR
MV-CEA has potent antitumor activity against breast cancer lines and xenografts and monitoring marker peptide levels in the serum could serve as a low-risk method of detecting viral gene expression during treatment and could allow dose optimization and individualization of treatment.
Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human neuroblastoma through a CD46 and nectin 4-independent pathway.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 37 REFERENCES
Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus.
TLDR
The results suggest that the oncolytic antitumor action of replication-competent HSV may be augmented by induction of specific and systemic antitUMor immunity effective both in the periphery and in the brain.
Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations.
TLDR
It is concluded that the SCID-hu mouse is a favorable host for studying the biology and therapy of myeloma and that a normal bone marrow environment can support the growth ofMyeloma cells.
Measles Virus Spread and Pathogenesis in Genetically Modified Mice
TLDR
It is concluded that in mice alpha/beta interferon controls MV infection and that a high-affinity receptor facilitates, but is not strictly required for, MV spread and pathogenesis.
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
TLDR
Vesicular stomatitis virus (VSV), an enveloped, negative-sense RNA virus exquisitely sensitive to treatment with interferon, is used as a replication-competent oncolytic virus and a new strategy for the treatment of interferons non-responsive tumors is demonstrated.
Single-Chain Antibody Displayed on a Recombinant Measles Virus Confers Entry through the Tumor-Associated Carcinoembryonic Antigen
TLDR
MV not only tolerates the addition of a scAb on its H protein but also infects cells via a novel interaction between the scAb and its targeted receptor.
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
TLDR
An E1A mutant adenovirus, dl922-947, is identified that replicates in and lyses a broad range of cancer cells with abnormalities in cell-cycle checkpoints, and holds promise as a potent, replication-selective virus for the local and systemic treatment of cancer.
Recombinant Measles Viruses Efficiently Entering Cells through Targeted Receptors
TLDR
These studies prove that MV can be engineered to selectively eliminate cells expressing a targeted receptor and provide insights into the mechanism of MV entry.
Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus
TLDR
Results show that the human CD46 molecule serves as an MV receptor allowing virus-cell binding, fusion, and viral replication and open new perspectives in the study of MV pathogenesis.
Measles Virus Infection in a Transgenic Model Virus-Induced Immunosuppression and Central Nervous System Disease
The development of a model for the homing of multiple myeloma cells to human bone marrow.
TLDR
This in vivo model of human MM provides for the first time a means for identifying adhesion molecules that are responsible for specific homing of human multiple myeloma cells to the human, as opposed to murine, BM microenvironment.
...
1
2
3
4
...